About us

HEMEO designs AI based Personalized Clinical Decision Support Systems to Prevent, Diagnose, and Treat Coagulation Disorders

WHY - Problem Statement

Currently, laboratory tests and treatment guidelines provide physicians restricted guidance to manage the bleeding and/or thrombosis risk for individual ICU patients, which leads to excess morbidity, mortality and costs.
Targeting ICU with our initial portfolio of solutions: ICU patients in general have a high risk of developing thrombosis and/or bleeding. No single laboratory test or guideline can inform physicians which patients to treat and in what manner, in order to prevent as much thrombosis and bleeding as possible.

WHAT - Hemeo’s Proposition

Hemeo’s core technology is a computational model of the blood coagulation system that has been perfected using the laboratory data from thousands of persons. When fed with a single patient’s laboratory data, the model can make personalized thrombosis and bleeding risk estimations and hence personalized treatment recommendations.
Embedded in Hemeo’s intuitive clinical decision support software, the model provides the physician with patient specific guidance to enable a significant reduction of the number of bleeding and thrombosis events in ICU patients.

Our Partners:

An NLC Venture

Exclusive license to 9 registered patents
based upon 15 years of research

An NLC Venture

Exclusive license to 9 registered patents
based upon 15 years of research

Our Team

remi

Remi Corlin

Chief Executive Officer

René van den Ham

Chief Technology Officer

Aamer Ahmed

Chief Medical Officer